Comparing Low Dose and Standard Dose Trimethoprim-Sulfamethoxazole to Treat Pneumocystis Jirovecii Pneumonia in Adults
Led by Todd C. Lee MD MPH FIDSA · Updated on 2026-02-20
416
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Pneumocystis jirovecii pneumonia PCP is a serious fungal infection that mainly affects people with weakened immune systems, such as those with HIV, organ transplants, cancer, or on immunosuppressive treatments. This research aims to compare the effects and safety of two different doses of the drug trimethoprim-sulfamethoxazole TMP-SMX to find the best treatment approach for PCP. The trial is a Phase III randomized, placebo-controlled study designed to address concerns about the side effects seen with the current standard dose of TMP-SMX.
Participants will receive either a reduced dose of TMP-SMX at 10 mgkgday or the standard dose at 15 mgkgday. The medication can be given orally or through an intravenous line, based on the treating teams choice. All doses will be adjusted for factors like obesity and kidney function. To maintain the studys blindness, patients in the reduced dose group will receive placebo tablets or solutions to mimic the higher dose, and those in the standard dose group will receive the full dose plus a masked portion to match the study design.
During the study, participants will be closely monitored for a range of outcomes including death, need for advanced respiratory support, severe side effects, changes in therapy, and length of hospital stay, all assessed within 30 days. Researchers will evaluate these measures to understand the safety and effectiveness of the lower dose compared to the standard dose. The trial includes detailed assessments and follows patients over this period to capture important health changes and treatment responses.
CONDITIONS
Brief Title
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
Research Team
B
Babykumari Chitramuthu, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Immunocompromised, including but not limited to HIV, solid organ transplant, solid tumors, hematological stem cell transplant and malignancies, systemic diseases, chemotherapy, long term corticosteroid use, and immunosuppressive therapies, as well as primary immunodeficiencies
Presentation to a day hospital, emergency department, or admitted to hospital
Proven or probable diagnosis of PCP using an adapted version of the 2021 EORTC/MSGERC criteria
You will not qualify if you...
Previous severe adverse reaction to TMP-SMX, any sulfa drug, or any component of formulation
Compliant with PCP prophylaxis for 4 weeks or more with TMP-SMX at enrollment
More than 96 hours of any therapy for PCP
Hepatic impairment marked by alanine aminotransferase levels 5 times the upper limit of normal
Known G6PD deficiency
Known diagnosis of porphyria
Known pregnancy or breastfeeding
Unable to provide informed consent and no available healthcare proxy; refusal of consent; no reliable means of outpatient contact
Previously enrolled
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 30 days
Participants receive low dose or standard dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia.
Duration reflects active treatment period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating Caspofungin Treatment for Pneumocystis Pneumonia in Adults with HIVAIDS
Comparing Caspofungin with Standard TrimethoprimSulfamethoxazole Therapy
Safety and Efficacy Study of Nebulized Caspofungin with Standard Antifungal Treatment for Pneumocystis Pneumonia A Phase III Randomized, Placebo-Controlled Trial
Developing and Testing the FUNGAL-P Clinical Prediction Score for Early Identification of Fungal Pneumonia in Adults with Pneumonia at Careggi University Hospital
Comparing Low Dose and Standard Dose Trimethoprim-Sulfamethoxazole to Treat Pneumocystis Jirovecii Pneumonia in Adults
Improving Diagnosis of Pneumocystis in Adults with Weakened Immune Systems Using Non-Invasive Tests
Phase 2 Study Comparing Rezafungin Plus 7 Days of Co-Trimoxazole Versus Co-Trimoxazole Alone
for Treating Pneumocystis Pneumonia in Adults with HIV
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial.
Zahra N Sohani, Guillaume Butler-Laporte, Andrew Aw...